{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:52:13Z","timestamp":1791910333173,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0506606"],"award-info":[{"award-number":["2023ZD0506606"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118312","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:04:09Z","timestamp":1785942249000},"page":"118312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Notoginsenoside R1 alleviates cholestatic liver fibrosis through modulation of the intestinal FXR-FGF15 axis and bile acid homeostasis"],"prefix":"10.1016","volume":"253","author":[{"given":"Min","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaolian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bairong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuming","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-7120","authenticated-orcid":false,"given":"Feng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10579","article-title":"Prospective therapeutics for intestinal and hepatic fibrosis","volume":"8","author":"Li","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118312_b0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.matbio.2018.04.006","article-title":"Liver fibrosis: direct antifibrotic agents and targeted therapies","volume":"68\u201369","author":"Schuppan","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.bcp.2026.118312_b0015","doi-asserted-by":"crossref","unstructured":"J. Mej\u00eda Ram\u00edrez, F. Higuera de la Tijera, C. Guzman, \u00c1.D. Santana Vargas, V. L\u00f3pez Ladron de Guevara, C.Y. S\u00e1nchez S\u00e1nchez, et al., Connective tissue growth factor assessment: determination of cut-off points for liver fibrosis in cholestasis, Ann. Hepatol. 30 (2025) 101988, https:\/\/doi.org\/10.1016\/j.aohep.2025.101988.","DOI":"10.1016\/j.aohep.2025.101988"},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3350\/cmh.2023.0506","article-title":"JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis","volume":"30","author":"Xie","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.bcp.2026.118312_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116833","article-title":"Astragalus saponins protect against extrahepatic and intrahepatic cholestatic liver fibrosis models by activation of farnesoid X receptor","volume":"318","author":"Zhang","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bcp.2026.118312_b0030","article-title":"Dual role of pregnane X receptor in nonalcoholic fatty liver disease","volume":"17","author":"Xu","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0035","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s10238-022-00919-9","article-title":"Hepatic vitamin D receptor expression is negatively associated with liver inflammation and fibrosis in patients with chronic HBV infection","volume":"23","author":"Yang","year":"2023","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0168-8278(00)80413-4","article-title":"New aspects of hepatic fibrosis","volume":"32","author":"Brenner","year":"2000","journal-title":"J. Hepatol."},{"issue":"15","key":"10.1016\/j.bcp.2026.118312_b0045","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0050","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep4.1490","article-title":"Bile acid changes associated with liver fibrosis and steatosis in the Mexican-American population of South Texas","volume":"4","author":"Kwan","year":"2020","journal-title":"Hepatol. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0055","doi-asserted-by":"crossref","first-page":"i173","DOI":"10.1093\/ecco-jcc\/jjab232.195","article-title":"P066 lower serum concentration of sulfated bile acids is associated with primary sclerosing cholangitis inflammatory bowel disease comorbidity and advanced liver fibrosis","volume":"16","author":"Leibovitzh","year":"2022","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0060","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hep.29289","article-title":"Linking long noncoding RNA to control bile acid signaling and cholestatic liver fibrosis","volume":"66","author":"Chiang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2026.118312_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114664","article-title":"Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis","volume":"379","author":"Suga","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111626","article-title":"Slit2 signaling contributes to cholestatic fibrosis in mice by activation of hepatic stellate cells","volume":"385","author":"Li","year":"2019","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0075","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/hep.30975","article-title":"Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice","volume":"71","author":"Liu","year":"2019","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.bcp.2026.118312_b0080","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.3748\/wjg.v27.i22.3010","article-title":"Role of bile acids in liver diseases mediated by the gut microbiome","volume":"27","author":"Shao","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00894-018-3886-2","article-title":"Roles of the inflammasome in the gut\u2013liver axis","volume":"19","author":"Wang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bcp.2026.118312_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1123967","article-title":"Liver's influence on the brain through the action of bile acids","volume":"17","author":"Yeo","year":"2023","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s10620-020-06208-3","article-title":"Deoxycholic acid-induced gut dysbiosis disrupts bile acid enterohepatic circulation and promotes intestinal inflammation","volume":"66","author":"Xu","year":"2021","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0100","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s40168-023-01709-5","article-title":"Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia","volume":"11","author":"Xu","year":"2023","journal-title":"Microbiome"},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0105","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1038\/s41467-022-34258-w","article-title":"Hepatic thyroid hormone signalling modulates glucose homeostasis through the regulation of GLP-1 production via bile acid-mediated FXR antagonism","volume":"13","author":"Yan","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118312_b0110","doi-asserted-by":"crossref","unstructured":"S. Modica, M. Petruzzelli, E. Bellafante, S. Murzilli, L. Salvatore, N. Celli, et al., Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis, Gastroenterology 142(2) (2012) 355\u201365.e1\u20134, https:\/\/doi.org\/10.1053\/j.gastro.2011.10.028.","DOI":"10.1053\/j.gastro.2011.10.028"},{"issue":"3","key":"10.1016\/j.bcp.2026.118312_b0115","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s12072-023-10636-4","article-title":"FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence","volume":"18","author":"Simbrunner","year":"2024","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12866-023-02774-4","article-title":"Human liver microbiota modeling strategy at the early onset of fibrosis","volume":"23","author":"Champion","year":"2023","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.bcp.2026.118312_b0125","article-title":"The gut microbiota-bile acid axis: a potential therapeutic target for liver fibrosis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bcp.2026.118312_b0130","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/19490976.2020.1732268","article-title":"The microbiome modulating activity of bile acids","volume":"11","author":"Tian","year":"2020","journal-title":"Gut Microbes"},{"issue":"3","key":"10.1016\/j.bcp.2026.118312_b0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jgr.2019.01.008","article-title":"New hydroperoxylated and 20,24-epoxylated dammarane triterpenes from the rot roots of Panax notoginseng","volume":"44","author":"Shang","year":"2019","journal-title":"J. Ginseng Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13075-021-02438-6","article-title":"Lymphatic muscle cells contribute to dysfunction of the synovial lymphatic system in inflammatory arthritis in mice","volume":"23","author":"Liang","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcp.2026.118312_b0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13578-019-0279-x","article-title":"PNS-R1 inhibits Dex-induced bronchial epithelial cells apoptosis in asthma through mitochondrial apoptotic pathway","volume":"9","author":"Zou","year":"2019","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3390\/molecules24020247","article-title":"Notoginsenoside R1 protects db\/db mice against diabetic nephropathy via upregulation of Nrf2-mediated HO-1 expression","volume":"24","author":"Zhang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2026.118312_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2023.105881","article-title":"The main bioactive compound of Panax notoginseng, notoginsenoside R1, alleviates pulmonary fibrosis via MBD2\/SHIP and STAT3 pathway","volume":"110","author":"Wang","year":"2023","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.bcp.2026.118312_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2024.106159","article-title":"Triterpenoid saponins from the roots of Panax notoginseng with protective effects against APAP-induced liver injury","volume":"178","author":"Tian","year":"2024","journal-title":"Fitoterapia"},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.113992","article-title":"Notoginsenoside R1 targets PPAR-\u03b3 to inhibit hepatic stellate cell activation and ameliorates liver fibrosis","volume":"437","author":"Guo","year":"2024","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0170","first-page":"511","article-title":"Notoginsenoside R1","volume":"50","author":"Gong","year":"2022","journal-title":"An Active Compound from Panax Notoginseng, Inhibits Hepatic Stellate Cell Activation and Liver Fibrosis via MAPK Signaling Pathway, Am J Chin Med"},{"issue":"7","key":"10.1016\/j.bcp.2026.118312_b0175","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41401-024-01250-7","article-title":"Notoginsenoside R1 promotes Lgr5(+) stem cell and epithelium renovation in colitis mice via activating Wnt\/\u03b2-Catenin signaling","volume":"45","author":"Yu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2026.118312_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116793","article-title":"Notoginsenoside R1 treatment facilitated Nrf2 nuclear translocation to suppress ferroptosis via Keap1\/Nrf2 signaling pathway to alleviated high-altitude myocardial injury","volume":"175","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2026.118312_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108074","article-title":"Multi-target neuroprotective effects of notoginsenoside R1 in neurodegenerative diseases: from pharmacokinetics to translational prospects","volume":"224","author":"Lin","year":"2026","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.118312_b0190","article-title":"Integrating network analysis and metabolomics to reveal mechanism of huaganjian decoction in treatment of cholestatic hepatic injury","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118312_b0195","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41396-019-0560-3","article-title":"The relationship between fecal bile acids and microbiome community structure in pediatric Crohn's disease","volume":"14","author":"Connors","year":"2019","journal-title":"ISME J."},{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0200","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s42255-019-0074-3","article-title":"Metabolic Messengers: fibroblast growth factor 15\/19","volume":"1","author":"Gadaleta","year":"2019","journal-title":"Nat. Metab."},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0210","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1038\/s41467-020-17363-6","article-title":"An FGF15\/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.bcp.2026.118312_b0215","article-title":"Yangonin protects against estrogen-induced cholestasis in a farnesoid X receptor-dependent manner","volume":"857","author":"Dong","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.117.246033","article-title":"Farnesoid X receptor agonists obeticholic acid and chenodeoxycholic acid increase bile acid efflux in sandwich-cultured human hepatocytes: functional evidence and mechanisms","volume":"365","author":"Guo","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.118312_b0225","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cbdv.200690074","article-title":"Ginsenoside Re and notoginsenoside R1: immunologic adjuvants with low haemolytic effect","volume":"3","author":"Sun","year":"2006","journal-title":"Chem. Biodivers."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0230","first-page":"3947","article-title":"Notoginsenoside R1 alleviates high glucose-evoked damage in RSC96 cells through down-regulation of miR-503","volume":"47","author":"Wang","year":"2019","journal-title":"Artif. Cells"},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/tnsci-2020-0118","article-title":"Notoginsenoside R1 attenuates sevoflurane-induced neurotoxicity","volume":"11","author":"Zhang","year":"2020","journal-title":"Transl. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4149\/av_2023_105","article-title":"Notoginsenoside R1 inhibits hepatitis B virus replication by modulating SIRT1 activity","volume":"67","author":"Zhang","year":"2023","journal-title":"Acta Virol."},{"key":"10.1016\/j.bcp.2026.118312_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115550","article-title":"Promising traditional chinese medicine for the treatment of cholestatic liver disease process (cholestasis, hepatitis, liver fibrosis, liver cirrhosis)","volume":"297","author":"Wei","year":"2022","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0250","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/hep.29676","article-title":"Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice","volume":"67","author":"Hartmann","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2026.118312_b0255","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2026.1821418","article-title":"Advances in research on the effects of bile acids and their receptors on intestinal function","volume":"13","author":"Cheng","year":"2026","journal-title":"Front. Nutr."},{"issue":"10","key":"10.1016\/j.bcp.2026.118312_b0260","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.mayocp.2020.01.015","article-title":"Cholestatic liver diseases","volume":"95","author":"Hilscher","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.bcp.2026.118312_b0265","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s12276-022-00737-9","article-title":"Sestrin2 protects against cholestatic liver injury by inhibiting endoplasmic reticulum stress and NLRP3 inflammasome-mediated pyroptosis","volume":"54","author":"Han","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"15","key":"10.1016\/j.bcp.2026.118312_b0270","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.3390\/cells11152344","article-title":"Hydrophobic bile salts induce pro-fibrogenic proliferation of hepatic stellate cells through PI3K p110 alpha signaling","volume":"11","author":"Zimny","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118312_b0275","doi-asserted-by":"crossref","unstructured":"H. Mori, G. Svegliati Baroni, M. Marzioni, F. Di Nicola, P. Santori, L. Maroni, et al., Farnesoid X receptor, bile acid metabolism, and gut microbiota, Metabolites 12(7) (2022) 647, https:\/\/doi.org\/10.3390\/metabo12070647.","DOI":"10.3390\/metabo12070647"},{"issue":"8","key":"10.1016\/j.bcp.2026.118312_b0280","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3390\/cells10081846","article-title":"Farnesoid X receptor as target for therapies to treat cholestasis-induced liver injury","volume":"10","author":"Petrescu","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0285","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.118312_b0290","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.28836","article-title":"Liver capsule: FXR agonists against liver disease","volume":"64","author":"Fuchs","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0295","first-page":"2953","article-title":"Regulation of Fgf15 expression in the intestine by glucocorticoid receptor","volume":"19","author":"Jia","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0300","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.devcel.2018.12.021","article-title":"FGF15 activates Hippo signaling to suppress bile acid metabolism and liver tumorigenesis","volume":"48","author":"Ji","year":"2019","journal-title":"Dev. Cell"},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0305","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13105-018-0610-8","article-title":"The ileal FGF15\/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice","volume":"74","author":"Li","year":"2018","journal-title":"J. Physiol. Biochem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0310","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.329","article-title":"Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich\u2010cultured human hepatocytes","volume":"5","author":"Zhang","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0315","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1124\/molpharm.121.000345","article-title":"Identification of key amino acids that impact organic solute transporter \u03b1\/\u03b2 (OST\u03b1\/\u03b2)","volume":"100","author":"Murphy","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118312_b0320","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jep.2015.12.033","article-title":"Geniposidic acid protected against ANIT-induced hepatotoxity and acute intrahepatic cholestasis, due to Fxr-mediated regulation of Bsep and Mrp2","volume":"179","author":"Chen","year":"2016","journal-title":"J. Ethnopharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118312_b0325","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/hep4.1262","article-title":"Calnexin depletion by endoplasmic reticulum stress during cholestasis inhibits the Na(+)-taurocholate cotransporting polypeptide","volume":"2","author":"Robin","year":"2018","journal-title":"Hepatol. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2026.118312_b0330","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000450983","article-title":"Bile acid uptake transporters as targets for therapy","volume":"35","author":"Slijepcevic","year":"2017","journal-title":"Dig. Dis."},{"key":"10.1016\/j.bcp.2026.118312_b0335","article-title":"Gut microbiota and metabolite insights into anti-obesity effect of carboxymethyl pachymaran in high-fat diet mice","volume":"111","author":"Wang","year":"2023","journal-title":"J. Funct. Foods"},{"issue":"7","key":"10.1016\/j.bcp.2026.118312_b0340","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/fsn3.2841","article-title":"Alteration of gut microbiota in high-fat diet-induced obese mice using carnosic acid from rosemary","volume":"10","author":"He","year":"2022","journal-title":"Food Sci. Nutr."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0345","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41598-020-58644-w","article-title":"Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn's disease","volume":"10","author":"Wilson","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0350","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.celrep.2018.12.028","article-title":"Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids","volume":"26","author":"Wang","year":"2019","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0355","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/jcsm.12798","article-title":"Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome","volume":"12","author":"Feng","year":"2021","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.bcp.2026.118312_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111036","article-title":"The gut microbiome-bile acid axis in hepatocarcinogenesis","volume":"133","author":"Wu","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0365","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12967-020-02539-x","article-title":"Gut microbiota from coronary artery disease patients contributes to vascular dysfunction in mice by regulating bile acid metabolism and immune activation","volume":"18","author":"Liu","year":"2020","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118312_b0370","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3390\/microorganisms10091792","article-title":"Bile acids: major regulator of the gut microbiome","volume":"10","author":"An","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.bcp.2026.118312_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118312_b0380","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2192155","article-title":"Glycoursodeoxycholic acid regulates bile acids level and alters gut microbiota and glycolipid metabolism to attenuate diabetes","volume":"15","author":"Chen","year":"2023","journal-title":"Gut Microbes"},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0385","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/19490976.2020.1732268","article-title":"The microbiome modulating activity of bile acids","volume":"11","author":"Tian","year":"2020","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0390","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3168\/jds.2020-19293","article-title":"Short communication: chemical structure, concentration, and pH are key factors influencing antimicrobial activity of conjugated bile acids against lactobacilli","volume":"104","author":"Wang","year":"2021","journal-title":"J. Dairy Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0395","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D'Amato","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.bcp.2026.118312_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115222","article-title":"Schisandrol B protects against cholestatic liver injury by inhibiting pyroptosis through pregnane X receptor","volume":"204","author":"Liang","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118312_b0405","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2026.118312_b0410","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2026.03.018","article-title":"FXR agonism in PSC recalibrated: how PRIMIS shapes endpoints and expectations for the next generation of trials","volume":"84","author":"Trampert","year":"2026","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0415","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70586","article-title":"An Update on Bile Acid-Regulated Signalling in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"46","author":"Shi","year":"2026","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0420","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000444544","article-title":"Novel aspects in the management of cholestatic liver diseases","volume":"34","author":"Chazouill\u00e8res","year":"2016","journal-title":"Dig. Dis."},{"key":"10.1016\/j.bcp.2026.118312_b0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.12.018","article-title":"Developments in bile salt based therapies: a critical overview","volume":"161","author":"Donkers","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118312_b0430","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.916866","article-title":"PPAR\u03b1: a potential therapeutic target of cholestasis","volume":"13","author":"Ye","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118312_b0435","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4014\/jmb.2111.11020","article-title":"Highly efficient biotransformation of notoginsenoside R1 into ginsenoside Rg1 by Dictyoglomus thermophilum \u03b2-xylosidase Xln-DT","volume":"32","author":"Li","year":"2022","journal-title":"J. Microbiol. Biotechnol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118312_b0440","doi-asserted-by":"crossref","first-page":"e4670","DOI":"10.1002\/bmc.4670","article-title":"Dose-dependent exposure profile and metabolic characterization of notoginsenoside R1 in rat plasma by ultra-fast liquid chromatography-electrospray ionization-tandem mass spectrometry","volume":"33","author":"Zhang","year":"2019","journal-title":"Biomed. Chromatogr."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:23:24Z","timestamp":1791908604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":88,"alternative-id":["S0006295226006519"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118312","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Notoginsenoside R1 alleviates cholestatic liver fibrosis through modulation of the intestinal FXR-FGF15 axis and bile acid homeostasis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118312"}}